Mallinckrodt plc (AMEX:MNK) shares traded 28.57% higher at $1.62 on Wall Street last session.
MNK stock price is now 1.26% away from the 50-day moving average and -77.90% away from the 200-day moving average. The market capitalization of the company currently stands at $26.07M.
In other news, Goodson Jason Daniel, EVP & Head of Corp Development bought 1,133 shares of the company’s stock on Mar 16. The stock was bought for $9,493 at an average price of $8.38. Upon completion of the transaction, the EVP & Head of Corp Development now directly owns 38,678 shares in the company, valued at $62658.36. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 15, Director SULAT JAMES R bought 15,000 shares of the business’s stock. A total of $128,155 was incurred on buying the stock at an average price of $8.54. This leaves the insider owning 82,553 shares of the company worth $0.13 million. Insiders disposed of 29,431 shares of company stock worth roughly $47678.22 over the past 1 year. A total of 0.59% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MNK stock. A new stake in Mallinckrodt plc shares was purchased by NOMURA HOLDINGS INC during the first quarter worth $548,000. BANK OF MONTREAL /CAN/ invested $428,000 in shares of MNK during the first quarter. In the first quarter, STIFEL FINANCIAL CORP acquired a new stake in Mallinckrodt plc valued at approximately $380,000. NOMURA ASSET MANAGEMENT CO LTD acquired a new stake in MNK for approximately $124,000. NATIONAL BANK OF CANADA /FI/ purchased a new stake in MNK valued at around $45,000 in the second quarter. In total, there are 68 active investors with 33.70% ownership of the company’s stock.
Mallinckrodt plc (AMEX: MNK) opened at $2.0500 on Thursday. During the past 12 months, Mallinckrodt plc has had a low of $0.41 and a high of $18.10. As of last week, the company has a debt-to-equity ratio of 2.26, a current ratio of 2.70, and a quick ratio of 1.40. The fifty day moving average price for MNK is $1.5770 and a two-hundred day moving average price translates $6.5625 for the stock.
The latest earnings results from Mallinckrodt plc (AMEX: MNK) was released for Mar, 2023. The net profit margin was -56.30% and return on equity was -59.80% for MNK. The company reported revenue of $424.6 million for the quarter, compared to $490.9 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.51 percent.
Mallinckrodt plc(MNK) Company Profile
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, hepatology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company was founded in 1867 and is based in Dublin, Ireland.
